Navigation Links
Fudan-Cinpathogen Study Shows Chronic Lymphoid Neoplasms are More Common in Shanghai Than Thought
Date:8/4/2008

A paper published in the International Journal of Hematology by scientists from the Fudan-Cinpathogen Clinical and Molecular Research Center at Fudan University, Shanghai, in collaboration with the University of Colorado, and Cincinnati Children's Hospital indicates that specific subtypes of chronic lymphoid neoplasms are not as rare in China as has been previously reported. Diagnosis and classification were performed by a single central laboratory in Shanghai according to WHO (2001) criteria making it largest prospective case series of lymphoid neoplasms in China published to date.

Shanghai, China (PRWEB) August 4, 2008 -- http://www.springerlink.com/content/r1623x466m24237r/ [A prospective study of 728 cases of non-Hodgkin lymphoma from a single laboratory in Shanghai, China] published online in the International Journal of Hematology shows significant differences in frequency of subtypes of lymphoma and other lymphoid neoplasms between China and the West. The report also reveals that chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), previously thought to be rare in China, is more common than suggested in earlier reports.

This publication is eighth in a series reporting research conducted by Cinpathogen scientists in collaboration with Fudan University, the University of Colorado, and Cincinnati Children's Hospital, that characterizes the features and frequency of hematopoietic disorders in China.

"Our study has increased medical knowledge and allowed us to help individual patients by sharing technological advancements," said Dr. Richard D. Irons, Cinpathogen CEO and the principal investigator of the project. "We are obtaining a better understanding of the prevalence of hematopoietic diseases in China, while at the same time having an impact on people's lives by providing the citizens of Shanghai the same advanced diagnostics that patients at modern Western medical centers receive."

A unique aspect of the 4 year Shanghai study is that diagnosis and classification were performed by a single central laboratory according to WHO (2001) criteria. This month's publication presents the results of the largest prospective case series of lymphoid neoplasms in China published to date. "It serves as an example that high-quality, state-of-the-art research is possible in China," explained Dr. Irons.

Cinpathogen operates the Fudan-Cinpathogen Clinical and Molecular Research Center providing diagnostics to patients from over 30 Shanghai area hospitals and conducting translational research on hematopoietic and lymphoid disorders in China. The Center offers specialized clinical capabilities that meet Western standards in the fields of hematology, molecular pathology, cytogenetics and flow cytometry.

For more information, visit http://www.cinpathogen.com [Cinpathogen's website] or contact our Boulder, Colorado ( 303-381-2543) or Shanghai ( 86-21-5423-7760) offices.

###

Read the full story at http://www.prweb.com/releases/2008/08/prweb1167414.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... The American ... Network (AHN), a Highmark Health company, to its Board of Trustees for a ... not-for-profit association of health care provider organizations and individuals that are committed to the ...
(Date:8/20/2017)... ... 20, 2017 , ... A total solar eclipse will occur across the U.S. on ... moon moves between the sun and Earth. This rare event will be magnificent to witness, ... keep you safe on the road during the total eclipse of the sun. , 1. ...
(Date:8/19/2017)... ... August 19, 2017 , ... ... Jr., will feature the Aurum Group in an upcoming episode, slated to air ... of Innovations will feature the Aurum Group; a company committed to supporting dentistry ...
(Date:8/19/2017)... New York, New York (PRWEB) , ... August ... ... Fruit Street Health has announced that it is the first organization with pending ... the CDC’s National Diabetes Prevention Program (“DPP”) via group telehealth classes and live ...
(Date:8/19/2017)... NJ (PRWEB) , ... August 19, 2017 , ... ... Park, NJ, is a diverse community of over 1,000 passionate employees, caregivers, volunteers, ... aging. After Parker at Stonegate changed ownership, it was time to refresh the ...
Breaking Medicine News(10 mins):
(Date:8/17/2017)... , Aug. 17, 2017 Bio-Ess Laboratories, LLC Chief Science Officer, ... titer and present new data on Cell-Ess® Universal Titer Boost ... Boston, MA August 21-25.  The Bioprocessing Summit convenes more ... challenges. ... ...
(Date:8/15/2017)...  Axium Pharmaceuticals Inc., the creator of the drug Truveta ... stages of an IPO. The United States ... cost of a prescription epilepsy drug being $450.00-$1200.00 for a one month ... AXIUM PHARMACEUTICALS, INC ... Another staggering figure is the fact that Americans spent $42 billion on ...
(Date:8/14/2017)... PETACH TIKVAH, Israel , Aug. 15, ... leading developer of adult stem cell technologies for neurodegenerative ... June 30, 2017. ... our pivotal Phase 3 trial to investigate NurOwn ® ... and Chief Executive Officer of BrainStorm. "We have agreements ...
Breaking Medicine Technology: